Answers are grounded in this paper and cite their sources.
// Artur Cieślar-Pobuda 1, 2, 3 , Mayur Vilas Jain 1 , Gunnar Kratz 2, 4, 5 , Joanna Rzeszowska-Wolny 3 , Saeid Ghavami 6 , Emilia Wiechec 1, 2 1 Department of Clinical and Experimental Medicine, Division of Cell Biology, Linköping University, Linköping, Sweden 2 Integrative Regenerative Medicine Center (IGEN), Linköping University, Linköping, Sweden 3 Institute of Automatic Control, Silesian University of Technology, Akademicka 16, Gliwice, Poland 4 Experimental Plastic Surgery, IKE, Linköping University, Linköping, Sweden 5 Department of Plastic Surgery, County of Östergötland, Linköping, Sweden 6 Department of Human Anatomy and Cell Science, University of Manitoba, Manitoba, Canada Correspondence to: Emilia Wiechec, e-mail: emilia.wiechec@liu.se Keywords: cancer stem cells, induced pluripotent stem cells, PFKFB3, PFK1, R-point Received: February 19, 2015 Accepted: August 03, 2015 Published: August 13, 2015 ABSTRACT Induced pluripotent stem cells (iPS) have become crucial in medicine and biology. Several studies indicate their phenotypic similarities with cancer stem cells (CSCs) and a propensity to form tumors. Thus it is desirable to identify a trait which differentiates iPS populations and CSCs. Searching for such a feature, in this work we compare the restriction (R) point-governed regulation of cell cycle progression in different cell types (iPS, cancer, CSC and normal cells) based on the expression profile of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase3 (PFKFB3) and phosphofructokinase (PFK1). Our study reveals that PFKFB3 and PFK1 expression allows discrimination between iPS and CSCs. Moreover, cancer and iPS cells, when cultured under hypoxic conditions, alter their expression level of PFKFB3 and PFK1 to resemble those in CSCs. We also observed cell type-related differences in response to inhibition of PFKFB3. This possibility to distinguish CSC from iPS cells or non-stem cancer cells by PFKB3 and PFK1 expression improves the outlook for clinical application of stem cell-based therapies and for more precise detection of CSCs.
No takes yet. Share an insight, caveat, or question.
Cieślar‐Pobuda et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: